SummaryRMgm-392
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 20227415 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | P. berghei ANKA cl15cy1 |
Other information parent line | A reference wild type clone from the ANKA strain of P. berghei (PubMed: PMID: 17406255). |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | L..A. Purcell; A. Rodriguez |
Name Group/Department | Department of Medical Parasitology |
Name Institute | New York University School of Medicine |
City | New York |
Country | USA |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-392 |
Principal name | pkrp- |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not different from wild type |
Fertilization and ookinete | Ookinete formation is reduced. This result is not based on counting ookinetes in vitro or in vivo but on quantitative PCR analysis of levels of 18S rRNA in mosquito midguts. |
Oocyst | Numbers of oocyst and of midgut-derived sporozoites are reduced. Transmission electron microscopy analyses of oocysts did not reveal any morphological differences wild type and mutant oocysts. |
Sporozoite | Numbers of oocyst and of midgut-derived sporozoites are reduced. A reduction (~75%)in the number of salivary gland sporozoites. Salivary gland sporozoites showed normal gliding motility, hepatocyte invasion, liver stage development and infectivity to mice. |
Liver stage | Numbers of oocyst and of midgut-derived sporozoites are reduced. A reduction (~75%)in the number of salivary gland sporozoites. Salivary gland sporozoites showed normal gliding motility, hepatocyte invasion, liver stage development and infectivity to mice. |
Additional remarks phenotype | Mutant/mutation See also RMgm-520 for an independen mutant lacking expression of PKRP (PBANKA_040940). Phenotype analyses of this mutant showed the following characteristics: Ookinete formation not different from wild type; Oocyst numbers (day12-14) reduced to 50% of wild type; Salivary gland sporozoite numbers reduced to 10% of wild type; No transmission by mosquito bite. The pkrp gene was targeted for complete deletion according to the gene model (PB001650.02.0) which was obtained from PlasmoDB. However, the latest Sanger sequencing and re-annotation effort has revealed that the pkrp ORF is much longer than initially described; the gene has now been re-named PBANKA_040940 (GeneDB). Consequently, this mutant has only part (i.e. N’ terminal deletion) of the ORF removed. Disruption of the P. falciparum ortholog, PFC0485w, has been reported by Agarwal, S et al. (2011; J Cell Biochem). In this paper no information on the phenotype of mutants with a disrupted PFC0485w gene is provided. Disruption of the P. falciparum ortholog has been attempted (Solyakov et al., 2011, Nat Commun, 2:565). After transfection with a KO vector a strong PCR signal diagnostic for gene disruption was observed in transfected populations indicating that this gene is not essential for asexual proliferation. Cloning will however be required to validate this interpretation for this |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_0409400 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0311400 | ||||||||||||||||||||||||
Gene product | protein kinase, putative | ||||||||||||||||||||||||
Gene product: Alternative name | putative kinase related protein; PKRP | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | Plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | KpnI, SacII | ||||||||||||||||||||||||
Partial or complete disruption of the gene | Partial | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | The pkrp gene was targeted for complete deletion according to the gene model (PB001650.02.0) which was obtained from PlasmoDB. However, the latest Sanger sequencing and re-annotation effort has revealed that the pkrp ORF is much longer than initially described; the gene has now been re-named PBANKA_040940 (GeneDB). Consequently, this mutant has only part (i.e. N’ terminal deletion) of the ORF removed. | ||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | |||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |